Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FABP6 | P51161 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21372201 | 0.81 | ALDH1A1 (0.35) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL13035938 | 0.81 | ALDH1A1 (0.35) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL12116975 | 0.81 | ALDH1A1 (0.50) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL29620781 | 0.81 | ALDH1A1 (0.35) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL24254608 | 0.81 | ADRA2A (0.37) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL25367179 | 0.79 | AR (0.36) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL3328643 | 0.78 | AR (0.35) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL3329757 | 0.78 | DHFR (0.34) | ALDH1A1GAAMAPTHSD17B10PIK3CD | |
| SCHEMBL16655910 | 0.78 | PIK3CD (0.33) | ALDH1A1GAAMAPTHSD17B10PIK3CD | |
| SCHEMBL13036607 | 0.78 | ALDH1A1 (0.36) | ALDH1A1GAAMAPTHSD17B10PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2356094-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010049302-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | GPBAR1, GPR119, GLP1R | ALDH1A1 341/4885GAA 1013/4885MAPT 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.